Research · Sep 3, 2026
[HRMY] Harmony Biosciences Thesis 2026: A Wakix-Narcolepsy + Pitolisant Compounder
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), headquartered in Plymouth Meeting, Pennsylvania, is a Wakix-Narcolepsy + emerging-multi-cycle-Pitolisant-Idiopathic-Hypersomnia + emerging-multi-cycle-Pediatric-Narcolepsy leader providing distinctive multi-cycle Wakix-Narcolepsy + emerging-Pitolisant-Idiopathic-Hypersomnia + emerging-Pediatric-Narcolepsy services to substantial multi-cycle US-Specialty-Pharmacy + Sleep-Medicine-Specialist + Neurologist + Pulmonologist + emerging-multi-cycle-Idiopathic-Hypersomnia-customer customer base. Distinctive multi-cycle Harmony-Biosciences-and-Plymouth-Meeting-PA-and-Wakix-Narcolepsy heritage: founded 2017 in Plymouth-Meeting-PA by John C. Jacobs; 2019 Wakix-FDA-approval; 2020 NASDAQ Harmony-Biosciences-IPO; 2024 Jeff Dayno President-and-CEO; 2024 substantial Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout; 2024 substantial Pediatric-Narcolepsy-Phase-3-readout. Multi-decade strategic-evolution: 2017 Harmony Biosciences founding; 2019 Wakix-FDA-approval; 2020 NASDAQ-IPO; 2024 Jeff Dayno CEO; 2024 substantial Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout; 2020-2025 substantial multi-cycle post-IPO + emerging-multi-cycle-Wakix-script-growth + emerging-multi-cycle-Pitolisant-IH + emerging-multi-cycle-Pediatric-Narcolepsy + emerging-multi-cycle-Pipeline-and-bolt-on-M&A. Under President & CEO Jeff Dayno (since 2024, ~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur), FY2025 closes with selected various aggregate revenue ~$720-820M, adj. EBITDA ~$285-355M, adj. EPS ~$4.20-5.50, net cash ~$0.40-0.55B, and ~58-62M shares outstanding. Wakix (pitolisant) is the first FDA-approved selective histamine-3 receptor antagonist/inverse-agonist for narcolepsy with or without cataplexy in adults (approved August 2019, first non-scheduled therapy for narcolepsy), patent-protected through ~2030+. The first deep-dive — Wakix-Narcolepsy + Pitolisant-Idiopathic-Hypersomnia + Pediatric-Narcolepsy franchise — covers entire Wakix-Narcolepsy + emerging-Pitolisant-IH + emerging-Pediatric-Narcolepsy business + Harmony-Biosciences positioning. Revenue mix: Wakix-Narcolepsy-and-Pitolisant-IH-and-Pediatric ~95-99% (largest-business + Other-CNS); Emerging-Other ~1-5%. Customer base: US-Specialty-Pharmacy + Sleep-Medicine-Specialist + Neurologist + Pulmonologist + emerging-Idiopathic-Hypersomnia-customer + emerging-Pediatric-Narcolepsy-customer. Distinctive multi-cycle 2024-Pitolisant-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy-Phase-3-readout. Competes with Jazz Pharmaceuticals (JAZZ largest-public-Narcolepsy-and-Sleep most-direct-larger-Jazz-Narcolepsy-comp + Xyrem + Xywav + Sunosi-divested-to-Axsome-2022), Axsome Therapeutics (AXSM + Sunosi + Auvelity), Avadel Pharmaceuticals (AVDL most-direct-Avadel-Lumryz-FT-218-Narcolepsy-comp + emerging-Lumryz-IH), Takeda Pharmaceutical (TAK + TAK-861-orexin-agonist-Phase-2-Narcolepsy), Centessa Pharmaceuticals (CNTA + ORX750-orexin-agonist-Narcolepsy-Phase-2), Alkermes (ALKS + ALKS-2680-orexin-agonist-Phase-2), Eli Lilly (LLY + orexin-Phase-1), Avadel (AVDL), Idorsia Pharmaceuticals (IDIA-SW + Quviviq), Allergan (AbbVie-ABBV-subsidiary), Pfizer (PFE), Bristol Myers Squibb (BMY), Novartis (NVS), AstraZeneca (AZN); Pediatric-Narcolepsy Jazz (JAZZ + Xywav-Pediatric); attention/CNS-specialty Supernus Pharmaceuticals (SUPN + Qelbree-and-GoCovri), Acadia Pharmaceuticals (ACAD + Nuplazid-and-Daybue), Acumen Pharmaceuticals (ABOS), Cerevel Therapeutics (AbbVie-ABBV-acquired 2024), Karuna Therapeutics (Bristol-Myers-Squibb-BMY-acquired 2024 + Cobenfy-schizophrenia), Sage Therapeutics (SAGE + Zurzuvae), Madrigal Pharmaceuticals (MDGL + Rezdiffra), Reata Pharmaceuticals (Biogen-BIIB-acquired 2023 + Skyclarys), Praxis Precision Medicines (PRAX), Otsuka Pharmaceutical (4578-T + Abilify-and-Rexulti), Lundbeck (HLUN-B-CO), Sumitomo Pharma (4506-T), Eisai (4523-T + Lecanemab), Biogen (BIIB), Roche (ROG-SW); orexin-receptor-agonist Takeda (TAK + TAK-861), Centessa (CNTA + ORX750), Alkermes (ALKS + ALKS-2680), Eli Lilly (LLY), Pfizer (PFE); private-pharma-pipeline Vanda Pharmaceuticals (VNDA + Hetlioz), Apnimed (private + AD109-OSA-Phase-3), Bioxcel Therapeutics (BTAI + Igalmi-and-BXCL501); private-equity-Specialty-Pharma TPG Capital (TPG), Apollo Global Management (APO), Carlyle Group (CG), Blackstone (BX + Blackstone-Life-Sciences), KKR (KKR), Permira (private), Cinven (private). The second deep-dive — Jeff-Dayno + 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout + multi-decade compounder thesis — covers Jeff-Dayno-CEO (~1+ year longtime-Harmony-CMO-and-Endo-Pharmaceuticals entrepreneur) expertise + Founder John C. Jacobs + multi-cycle-Harmony-Biosciences-Capital-Management leadership-continuity, 2024-Pitolisant-Idiopathic-Hypersomnia-Phase-3-readout + 2024-Pediatric-Narcolepsy-Phase-3-readout transformational-platform + multi-cycle-disciplined-bolt-on-M&A, emerging-multi-cycle US-and-international-Narcolepsy-and-Idiopathic-Hypersomnia-and-Pediatric-Narcolepsy + emerging-disease-awareness-and-diagnosis + emerging-Pipeline structural-tailwinds. Multi-cycle no-dividend (growth-stage) + multi-cycle-modest-share-buyback ($50-150M/yr). Multi-decade compounder thesis combines Harmony-Biosciences-and-Plymouth-Meeting-PA ~8+ year heritage (founded 2017 + 2020 NASDAQ-IPO), ~400+ employees + ~globally-positioned-Specialty-Pharma-facilities, 2024-Pitolisant-IH-and-Pediatric-Narcolepsy-Phase-3-readout + multi-cycle-disciplined-bolt-on-M&A, Jeff Dayno + Endo-Pharmaceuticals + Harmony-Biosciences expertise, no-dividend + multi-cycle-modest-share-buyback + IG-equivalent-and-Specialty-Pharma-debt-light balance-sheet, emerging-Narcolepsy-and-IH-and-Pediatric + emerging-disease-awareness + emerging-Pipeline structural-tailwinds. Capital position is IG-equivalent-and-Specialty-Pharma-debt-light, no-dividend (growth-stage) + multi-cycle-modest-share-buyback, conservative: net cash ~$0.40-0.55B (multi-cycle-net-cash + Specialty-Pharma-debt-light), IG-equivalent rating, $0.45-0.65B liquidity, no-dividend + ~$50-150M/yr buyback + multi-cycle-disciplined-bolt-on-M&A + emerging-Pitolisant-IH-and-Pediatric-and-Pipeline capex, ~58-62M shares. At ~$30-50 per share, equity value ~$1.7-3.1B, EV ~$1.3-2.6B, ~6-12x EPS and ~3.5-7.0x EV/EBITDA. Base case: Wakix-script-growth constructive + emerging-Pitolisant-IH-launch + emerging-Pediatric-Narcolepsy-launch + revenue $800-900M + adj. EBITDA $315-395M + adj. EPS $4.75-6.10 + ~5-15% return. Bull case: Wakix-script-growth accelerates + emerging-Pitolisant-IH inflects-substantially + emerging-Pediatric-Narcolepsy inflects-substantially + emerging-Pipeline-and-bolt-on-M&A inflects + revenue $850-960M + adj. EPS $5.30-6.75 + selective-M&A + emerging-strategic-acquisition-target (Jazz-Pharmaceuticals + Axsome + Avadel + Takeda + AbbVie + Pfizer + Eli-Lilly + Bristol-Myers-Squibb + Novartis + AstraZeneca + private-equity-Specialty-Pharma interest) + re-rate 8-15x + 25-50%+ return + takeout-premium-upside. Bear case: Wakix-script-growth stresses + emerging-orexin-receptor-agonist-competitive-threat-from-Takeda-Centessa-Alkermes-Lilly + emerging-Lumryz-IH-from-Avadel + adj. EPS $2.50-3.30 + de-rate 4-7x + flat-to-substantially-negative.